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ABSTRACT OF THE DISSERTION 
Madhankumar Sonachalam 
INTEGRATIVE SYSTEM BIOLOGY STUDIES ON HIGHTHROUGHPUT GENOMIC AND PROTEOMIC 
DATASET FOR BIOLOGICAL PATHWAY DISCOVERY 
The post genomic era has propelled us to the view that the biological systems are complex 
network of interacting genes, proteins and small molecules that give rise to biological form and 
function. The past decade has seen the advent of number of new technologies designed to study 
the biological systems on a genome wide scale. These new technologies offers an insight in to 
the activity of thousands of genes and proteins in cell thereby changed the conventional 
reductionist view of the systems. However the deluge of data surpasses the analytical and critical 
abilities of the researches and thereby demands the development of new computational methods. 
Gene expression microarrays can take a snapshot of all the transcriptional activity in a biological 
sample, while it also generates a huge amount of data with intrinsic noise (sample or instrument 
noise), which is still a quite challenging task to interpret it even by exploiting modern 
computational and statistical tools. The challenge no longer lies in the acquisition of gene 
expression profiles, but rather in the interpretation for the results to gain insights into biological 
mechanisms. Gene Set Enrichment Analysis (GSEA) is one of the widely used Gene Set 
Analysis (GSA) methods that aim to test the activity of gene clusters rather than individual 
genes.  
In Chapter 2, we integrated prior knowledge from gene signatures (curated gene sets from 
MSigDB and/or GeneSigDB); gene set enrichment analysis (GSEA), and gene/protein network 
modeling to identify gene network signatures from microarray data. We demonstrated how to 
apply this approach in discovering gene network signatures for colorectal cancer (CRC) from  
  viii 
 
microarray datasets. We compared the network generated from two different gene set sources 
and showed that the integrated network generated from both MSigDB and GeneSigDB can be 
used to identify novel pathways involved in colorectal cancer. 
In Chapter 3, we identified plasma based Subnetwork signatures for Alzheimer’s disease (AD) 
using proteomics dataset. Current plasma based AD signatures uses feature selection methods 
that was originally designed for microarray analysis. We evaluated various feature selection and 
classification approaches to select the best set of features for a specific proteomics dataset. Our 
combination of feature selection and classification techniques showed better performance than 
the existing results and we further provided biological validation by identifying relevant 
Subnetwork signatures. 
Finally, we applied the network based strategy to identify the role of MicroRNA in Myeloid 
Derived Suppressor Cells (MDSC) induced T-Cell Suppression. In Chapter 4, we used network 
based ranking algorithm to prioritize miRNA and genes by utilizing both network topology and 
differential information. We showed that the global and local topology characteristics of the 
miRNA-gene-gene/protein network along with the differential expression values obtained from 
microarray experiment can be used to identify biologically significant pathways. 
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1. INTRODUCTION 
1.1 Motivation 
The term omics refers to the comprehensive analysis of biological systems. A variety of 
omics disciplines have begun to emerge after the Human Genome Project. Genomics deals with 
the systematic use of genomic information and it includes investigations about the function of the 
genes. Transcriptomics examines the expression level of mRNAs of the genes in a given cell 
population. Proteomics focus on the large scale study of proteins while Metabolomics addresses 
the metabolites involved in the cellular process.  
System biology is the study of biology through the systematic perturbation, global read 
out of the multifaceted response through various omics studies and integration of those data to 
formulate predictive models. System biology investigates the behavior and relationships of all 
the elements in a biological system rather than focusing on a single gene or protein.  As a result, 
inputs from various disciplines such as statistics, computer science and mathematics are 
necessary to a “systems” approach of analyzing data. We employed system biology techniques to 
solve complex biological problems using genomics, proteomics and integrated MicroRNA and 
gene expression dataset.   
1.2 Messages 
The sheer volume of data generated in the post genomic era surpasses the analytical and 
critical abilities of a single researcher and demands the new computational methods to assist in 
the analysis of these data. In these projects, we devised new methodologies, integrated existing 
machine learning and network biology techniques to solve various complex biological problems. 
We adapted different strategies depending on the data sets that we are handling; genomics data 
sets are filtered using gene set enrichment techniques and integrated it with network biology to 
explore biological mechanism of colorectal cancer. While for proteomics data, we evaluated 
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various feature selection and classification algorithms to select best features which were then 
used to identify sub-network signatures.  Finally, we combined the miRNA and gene 
transcriptomics data to generate an integrated network which explains the molecular mechanism 
of T-cell suppression in cancer. 
1.3 Microarrays 
Gene expression microarrays can take a snapshot of all the transcriptional activity in a 
biological sample, while it also generates a huge amount of data with intrinsic noise (sample or 
instrument noise), which is still a quite challenging task to interpret it even by exploiting modern 
computational and statistical tools. These high-throughput genomics technologies have 
tremendously changed biomedical research, which allow researchers to simultaneously monitor 
the expression of tens of thousands of genes [1]. Microarray data analysis has also become a 
common practice in many experimental laboratories. Numerous literatures describe the 
innovative insights within microarray data analysis [2, 3]. It has been widely applied into many 
medical areas, including distinguishing disease subtypes [4], identifying candidate 
biomarkers[5], and revealing the underlying molecular mechanisms of disease [6] or drug 
response [7]. There are several repositories such as Gene Expression Omnibus (GEO) and Array 
Express that hosts Microarray dataset from various experiments. 
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2. SYSTEMS BIOLOGY APPROACH TO IDENTIFY GENE NETWORK SIGNATURES FOR COLORECTAL 
CANCER 
2.1 Background 
In microarray analysis, crucial genes show relatively slight changes, and many genes selected 
are also poorly annotated [2]. From a biological perspective, functionally related genes often 
display a coordinated expression to accomplish their roles in the cell [8]. Hence, to translate such 
lists of differentially expressed genes into a functional profile will help us to understand the 
underlying biological phenomena, one approach to aid interpretation is to look for changes in a 
group of genes  with a common function (gene cluster) [2]. 
Accordingly, Gene Set Analysis (GSA) methods aim to test the activity of such gene clusters 
instead of testing the activity of individual genes - individual gene analysis (IGA) [9]. In recent 
years, GSA approach has received a great deal of attention, since it is free from the problems of 
the ‘cutoff-based’ methods. In this direction, GSA methods enable the understanding of 
cellular processes as an intricate network of functionally related components [8].Among these 
GSA methods, gene set enrichment analysis (GSEA) is one of the most widely used methods 
[10]. GSEA analyzes pre-defined gene sets based on prior biological knowledge to determine 
whether this gene set as a whole exhibits differential expression. GSEA has many advantages as 
it does not employ an arbitrary cutoff to select significant genes. Instead, it uses all the 
information about every gene involved in the experiment. However, GSEA does rely on pre-
defined gene sets (without gene interaction information); making IGA more beneficial when not 
much is known about the biological function being considered. Furthermore, GSEA still assumes 
that more differentially expressed genes are more crucial to the biology, which is not always true 
[11]. In many cases, extensive upstream data processing, comprehensive gene selection statistics, 
and downstream pathway/network analysis cannot be replaced by GSEA. Therefore, gene 
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expression signature analysis and pathway analysis (using tools such as DAVID [12]) remain 
two separate processes. 
Network-based gene expression analysis is proposed for candidate biomarker discovery by 
integrating disease susceptibility genes, their gene expressions, and their gene/protein interaction 
network [13, 14]. In 2007, Marc Vidal’s group at Harvard constructed a protein interaction 
network for breast cancer susceptibility using various ‘omics’ data sets, and identified HMMR as 
a new susceptibility locus for the disease[13]. Later, Trey Ideker’s group at UCSD integrated 
protein network and gene expression data to improve the prediction of metastasis formation in 
patients with breast cancer [14]. The two studies marked the exciting beginning of a new 
paradigm which suggests networks and pathways, although drafty, error-prone, and incomplete, 
can serve as a molecular-level conceptual roadmap to guide future microarray analysis. 
Recent advances in genomics, transcriptomics, proteomics, epigenomics, and metabolomics 
have begun to help discover DNA/RNA-based prognostic and predictive markers for early and 
advanced colorectal cancer (CRC) [15]. Systems biology results show that cancer genes and 
proteins do not function in isolation; instead, they work in interconnected pathways and 
molecular networks [16]. However, systematically building disease-specific network models, 
integrated at multiple Omics level - transcriptome (RNA-based markers from microarray data) 
and proteome (protein-based markers from network and pathway data), has not yet been done in 
CRC biomarker discovery. 
In this work, we integrated prior knowledge from GWAS studies or gene signatures (curated 
gene sets from MSigDB and/or GeneSigDB), gene set enrichment analysis (GSEA), and 
gene/protein network modeling together to identify gene network signatures from microarray 
data. We demonstrated how to apply this approach into discovering gene network signatures for 
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colorectal cancer (CRC) from microarray datasets at three levels - genome, transcriptome, and 
proteome. First, we use GSEA to analyze the microarray data through enriching differential 
genes in different CRC-related gene sets from two publicly-available up-to-date gene set 
databases - Molecular Signatures Database (MSigDB) and Gene Signatures Database 
(GeneSigDB). Second, we compare the enriched gene sets through enrichment score (ES), false-
discovery rate (FDR) and nominal p-value. Third, we construct an integrated protein-protein 
interaction (PPI) network through connecting these enriched genes by using a human annotated 
and predicted protein interaction (HAPPI) database, with a confidence score (CS) labeled for 
each interaction. Finally, we map differential expression values onto the constructed network to 
build a comprehensive network model containing visualized genome, transcriptome, and 
proteome data. The results show that although MSigDB is more suitable for GSEA analysis than 
GeneSigDB, the integrated PPI network connecting the enriched genes from both MSigDB and 
GeneSigDB can provide more complete view for discovering gene signatures. We also find 
several important sub-network signatures for colorectal cancer, such as TP53 sub-network, 
PCNA sub-network and IL8 sub-network, corresponding to apoptosis, DNA repair, and immune 
response respectively. 
2.2 Methods 
2.2.1 Microarray data 
From GEO (http://www.ncbi.nlm.nih.gov/geo/), we download a CRC-related microarray 
dataset - GSE8671, which compared the transcriptomes of 32 prospectively collected adenomas 
with those of the normal mucosa from the same individuals. Hence we have 32 CRC samples 
and 32 normal samples. We use maximal expression values for same proteins mapped from 
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different Probe IDs. We use Affy package in BioConductor for quantile normalization. For 
background correction, we use the built-in MicroArray Suite (MAS5).  
2.2.2 Gene sets 
Gene sets are obtained from MSigDB and GeneSigDB. MsigDB has almost 6769 gene sets 
and are divided in to five major collections, of which “C2” are curated gene sets collected from 
various sources such as online pathway databases, publications in pubmed, and knowledge of 
domain experts. We searched in that collection with keyword “colon” and obtained 73 gene sets. 
GeneSigDB is a manually curated database of gene expression signatures. And it shares 
minimum overlap between MSigDB C2 Category of around 8%. It provides the standardized 
gene list for different search criteria. Searching as “Colon” had retrieved 36 gene sets. 
2.2.3 Gene set enrichment analysis 
Though there are many variations on the GSEA method, we describe the version of the algorithm 
developed by Subramanian and colleagues [10], which will be called the standard 
implementation of the method, since it is the most widely used form of the GSEA method. 
Suppose that a microarray dataset is obtained from two different phenotypes, phenotype 1 and 
phenotype 2 (e.g. control vs. experimental). This microarray dataset has expression values for the 
genes across the samples and each row has been identified by unique probe identification. 
Consider also a given gene set S, usually derived from some common biological category. The 
objective of the GSEA method is to see if the gene set S shows differential expression between 
the two phenotypes. 
The Broad Institute provides an easy to use standalone Java implementation of the GSEA 
method on their website (http://www.broadinstitute.org/gsea/). All gene sets with more than 500 
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genes or less than 15 genes were automatically excluded. The difference between signal-to-noise 
ratios was used as the association score. The number of phenotype permutations involved in the 
nominal p-value calculation was 1000. For each analysis, we report the number of gene sets with 
FDR<25%. Along with these gene sets with FDR<25%, we report the number of gene sets 
whose nominal p-values are <1% or 5%.  
2.2.4 Network modeling 
To optimize computation time and information generation, we use a combined network 
construction strategy, based on the enriched genes from both MSigDB and GeneSigDB. 
First, we connect the enriched MSigDB genes from GSE8671 in HAPPI 
(http://bio.informatics.iupui.edu/HAPPI) with confidence score (CI >=0.75, i.e. 4-star rating) for 
interactions, to obtain a protein-protein interaction (PPI) network. The local topological property 
(e.g. node degree, cluster coefficient, betweenness centrality, neighborhood connectivity etc. 
[17]) for each node is calculated based on this network. Then genes with absolute fold change 
|FC|>=1.5, equals to Log 2(FC)>=0.585, are kept. 
Second, we connect the enriched GeneSigDB genes from GSE8671 in HAPPI 
(http://bio.informatics.iupui.edu/HAPPI) with confidence score (CI >=0.75, i.e. 4-star rating) for 
interactions, to obtain another protein-protein interaction (PPI) network. In the same way, the 
local topological property for each node is calculated based on this network. Then genes with 
absolute fold change |FC|>=1.5, equals to Log 2(FC)>=0.585, are kept. 
Finally, we combine these two networks to build a node-weighted edge-scored CRC-specific 
PPI network model by using Cytoscape [18], with node color representing the fold change for 
each gene, node size representing the local topological property for each gene/protein, edge color 
and edge width representing confidence score for each protein interaction. 
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2.3 Results 
2.3.1 Enriched gene sets 
We run the GSEA analysis for the gene expression microarray data - GSE8671 with gene 
sets obtained from MSigDB and GeneSigDB separately. We use the default values in GSEA 
which filtered out 22 gene sets from MSigDB as the number of genes in those sets falls below 
the threshold value of 15 in GSEA. So we run the GSEA analysis on remaining 51 gene sets. Of 
those 51, 22 gene sets are up-regulated in normal and remaining 29 are up-regulated in cancer 
samples. Summary of the results are shown in Table 1. 
There are 22 gene sets that are significantly enriched in normal and 29 in Colorectal cancer, 
of which the gene set - GRADE_COLON_CANCER_DN tops the list with enrichment score of 
0.79 in Normal vs. Cancer, and  the gene set - SANA_RESPONSE_TO_IFNG_DN tops 
the list in Cancer vs. Normal with the enrichment score of -0.67.  
Table 1: Summary of CRC Gene Set Results enriched in MSigDB 
Enrichment Normal vs. Cancer Cancer vs. Normal 
Up-regulated 22 gene sets  29 gene sets 
Significant at FDR < 25% 8 gene sets  14 gene sets 
Nominal p-value for S from ESNULL < 5% 7 gene sets  12 gene sets 
Nominal p-value for S from ESNULL < 1% 5 gene sets  6 gene set 
As with the case of MSigDB, GSEA had filtered only 22 gene sets out of 34 based on the 
default filter criteria. Of these 22, 11 gene sets are enriched in normal and remaining 11 on 
cancer. Summary of the results are shown in table 2.  Of the enriched gene sets - 16091735-
TABLE1 tops the list in Normal vs. Cancer with the enrichment score of 0.52 and the gene set - 
11906190-TABLE2B-2 tops the list with enrichment score of -0.53 in Cancer vs. Normal.  
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Table 2: Summary of CRC Gene Set Results enriched in GeneSigDB 
Enrichment Normal vs. Cancer Cancer vs. Normal 
Up-regulated 11 gene sets  11 gene sets 
Significant at FDR < 25% 7 gene sets  8 gene sets 
Nominal p-value for S from ESNULL < 5% 4 gene sets  5 gene sets 
Nominal p-value for S from ESNULL < 1% 1 gene sets  2 gene set 
 
2.3.2 A PPI network based on enriched genes from MSigDB 
We construct a PPI network (325 genes and 686 interactions) with CI >=0.75 based on the 
694 enriched genes (mapped to 678 proteins) from MSigDB, and visualize the network layout by 
using spring embedded network layout in Cytoscape 2.8.1. After filtering out genes with 
|FC|<1.5, there are 244 genes and 422 interactions. We also map the differential expression 
values onto the genes in the network by representing them as node colors. Since we also simply 
represent node degree as node size, we can easily access the relationship between differential 
expression value and topological property for each gene in the network. As shown in Figure 1, 
the gene sets from MSigDB connected very well. Most important cancer genes, such as TP53 
and PCNA, related to apoptosis and DNA repair are included. It indicates that MSigDB is 
suitable for GSEA analysis, unsurprisingly, since MSigDB is generated by the same group which 
developed GSEA. 
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TP53 sub-network, PCNA sub-network and IL8 sub-network, corresponding to apoptosis, DNA 
repair, and immune response respectively [19-21]. 
However, gene-to-gene or gene-to-protein interaction may be even more accurately 
represented by a network. One limitation of our restrictive approach and of the GSEA method in 
general, is that it is not able to generate new hypotheses for unsuspected gene sets. This has 
proved to be a major limitation of the GSEA method in general, especially since one of the main 
goals of gene expression microarray analysis is to find new sets of relevant genes. Another 
disadvantage of the GSEA method is that genes that are more differentially expressed are 
assumed to be more crucial.  However, this assumption has not been thoroughly tested. 
Currently, it is important to realize that no single method of gene expression microarray 
analysis works best, but rather information generated by the different analyses should be 
integrated together with the knowledge from biological research. In future work, we aim to 
combine GSEA, gene ontology (GO) enrichment, network expanding/enriching methods 
together to identify biologically significant genes/proteins. We will use more gene expression 
microarray datasets to validate this integrated strategy. We will also use newly generated gene 
expression profiles by using RNA-sequencing (RNA-seq) technique to test our new hypothesis. 
 
3. IENTIFYING PLASMA-BASED SUBNETWORK SIGNATURES FOR ALZHEIMER’S DISEASE USING A 
MULTIPLEX PROTEOMIC IMMUNOASSAY PANEL 
3.1 Background 
Currently, the only way to confirm Alzheimer’s disease (AD) definitively comes from autopsy, 
with the presence of characteristic lesions in the brain caused by extracellular plaques of 
Amyloid β (Aβ) peptide and intracellular neurofibrillary tangles (NFTs) formed by 
hyperphosphorylated Tau protein [22]. Intensive research has been conducted for discovering 
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reliable AD biomarkers in peripheral blood. Although there are many publications on potential 
plasma-based AD biomarkers, follow-up studies by other research groups have often failed to 
show accurate, efficient and consistent diagnostic values [23]. There is an urgent need for 
benchmarks to be able to evaluate the performance of these biomarker panels/signatures. 
Moreover, it also remains unknown what relationships between proteins within each signature, 
and what relationships between these signatures are involved. 
In 2007, Ray et al. [24] screened 120 proteins involved in cell communication, and found a 18-
protein signature that can be used to classify blinded samples from Alzheimer’s and control 
subjects with close to 90% accuracy. Their analysis was based on a shrunken centroid algorithm 
called predictive analysis of microarrays (PAM), with 83 archived plasma samples as training set 
and 92 separate samples as testing set (AD against control). Biological interpretation based on 
these 18 signaling proteins indicates systemic dysregulation of hematopoiesis, immune 
responses, apoptosis and neuronal support in presymptomatic AD. This pilot study has made a 
significant contribution for discovering diagnostically useful plasma-based AD biomarkers. 
In 2008, using the same proteomic data, Gomez and Moscato [25]  reported a 5-protein signature 
(which is a subset of the 18-protein signature) that achieves, on average, a 96% total accuracy in 
predicting clinical AD (80 for training and 92 for testing). This 5-protein signature (the 
abundance of IL-1α, IL-3, EGF, TNF-α and G-CSF) was chosen by using their spectacular 
feature selection approach based on Fayyad and Irani's entropy minimization algorithm, which 
was originally designed for microarray analysis [26]. The 5-protein signature demonstrated the 
same performance with the original 18-protein signature when using the same classifiers, such as 
Simple Logistic or Logistic Model Trees. The performance was verified by using over 20 
different classifiers available in the widely-used Weka software package [27]. In 2011, by using 
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methods from combinatorial optimization and information theory, Moscato’s team reanalyzed 
the same proteomic data, and uncovered novel biomarkers, which confirms ANG-2, IL-11, 
PDGF-BB, CCL15/MIP-1δ; and supports the joint measurement of other signaling proteins not 
previously discussed: GM-CSF, NT-3, IGFBP-2 and VEGF-B [28]. 
Although the accuracy reported for these two plasma-based AD signatures are high enough, the 
consistency for their stable clinical application still remains unknown, especially when 
evaluating these signatures in new cohorts. In 2009, Soares et al. tested the reproducibility of 
another subset of the 18-protein signature by using quantitative multiplex proteomic 
immunoassay, which suggest diagnostic accuracy using this subset can only achieved 61%. By 
using multivariate analysis for feature selection and linear discriminant and random forest 
analysis for classification, an 89-protein signature was found, which can yield a diagnostic 
accuracy of 70%. This result suggests that the current plasma-based AD signatures may be useful 
as AD screening tools, but are still far from AD diagnostic purpose. 
Another major concern on the view of bioinformatics is that the current plasma-based AD 
signatures are all selected by the feature selection approaches originally designed for microarray 
analysis. The performance of these approaches is doubtful when applying to proteomic studies 
(typically 120-250 protein analytes) with much less feature than in high-throughput 
transcriptomic studies (generally 20,000 genes or 50,000 probes). Feature selection is used as a 
preprocessing step before building models for classification. It aims to limit the amount and 
dimensionality of the data and thereby selecting significant features that correlate well with the 
target class [29-31]. Feature selection methods are often categorized as filters, wrappers, or 
embedded methods depending on how they combine the feature selection search with the 
construction of the classification model [32].  
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Filter methods evaluates each feature by looking only at the intrinsic properties of the data.  Most 
methods works by assigning a score value for each feature and set a threshold as a criterion to 
evaluate performance. If the score values of a feature is greater than the threshold, then the 
feature will be selected otherwise it will be removed. Filter methods can rely on univariate and 
multivariate statistics [33].  Univariate methods such as chi square and Pearson correlation 
assumes each attribute as independent and assess the relevance of individual attributes for a 
specific class at a time [34]. In this kind of analysis, attributes that are not individually relevant 
but become significant in the context of other attributes will be missed out. Since univariate 
features selection methods are not able to capture feature interactions, it can result in redundant 
features which have high score with the class. Multivariate methods such as ReliefF overcome 
this constraint by considering feature interactions [33]. 
The wrapper approach uses search algorithms to select various subsets of features in the space of 
possible subsets, and evaluates the specific subset of features using a specific classification 
model [29, 30]. Wrapper methods consider the feature dependencies and since there is an 
interaction between the feature subset and the model selection, it helps to select best subset. 
Embedded methods also involve classification models, but unlike wrapper methods, the search 
for an optimal subset of features is built in to the classifier construction. Since it perform feature 
selection as a part of the classifier training process it takes computationally less time than 
wrapper[33]. SVM Attribute Evaluator and Elastic Net are some well-known embedded methods 
[35]. These methods are very effective in dealing with genomics and proteomics dataset in 
various bioinformatics approach. The main drawback with these methods is they do not integrate 
any external knowledge source to explain the biology behind the interactions. 
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In this work, we developed five criteria – accuracy, efficiency, consistency, significance and 
connectivity, to evaluate different feature selection approaches for identifying protein biomarkers 
under varied conditions. We compared 15 feature selection approaches and 20 classification 
methods in Weka [27] on a new dataset generated from the samples (AD vs. health control) 
collected by Alzheimer's Disease Neuroimaging Initiative (ADNI). We chose five feature 
selection approaches – ReliefF, SVM, OneR, Elastic Net and lasso for thorough evaluation on 
the presented five criteria, according to their overall performance on accuracy. Based on the top 
32 protein analytes selected by each of these five feature selection approaches, we finally built a 
64-protein network consisting of four subnetworks, which are defined as subnetwork signatures 
here. We also compared the protein analytes in the network with those analytes in the existing 
plasma-based AD signatures, and found these four plasma-based AD subnetwork signatures 
corresponding to G-Protein coupled receptor (GPCR) ligand pathway activation, complement, 
immune response, and apoptosis respectively. In these functions, GPCR ligand pathway 
activation is newly reported for plasma-based AD signatures, especially the important role of an 
analyte –follicle stimulating hormone (FSH), which bridges the functional subnetworks of 
hemostasis and apoptosis. 
3.2 Methods 
3.2.1 ADNI multiplex proteomic immunoassay data collection 
We used the ADNI dataset providing expression values for 146 analytes in 108 Alzheimer 
disease patients and 53 healthy controls which we call as master dataset. We randomly permuted 
the master dataset to create 20 partitions with same number of Alzheimer and healthy samples. 
Then we approximately halved each partition in to training and testing set thereby maintaining 
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equal samples for both class in training and testing set say 53-54 samples of Alzheimer and 26-
27 samples of Healthy control. 
3.2.2 Feature selection and Classification 
Waikato Environment for knowledge analysis suite (Weka, version 3.6) was used for applying 
classification and feature selection methods to our datasets [27]. Weka is a java based tool that 
provides implementations for various machine learning algorithms. Weka has been used for 
various genomics and proteomics studies in Bioinformatics [36]. The default parameters set 
within Weka has been used for all the attribute selection and classification method. We are aware 
that the results can be optimized by tuning the parameters for classification algorithm, since we 
are interested in selecting possibly best features for downstream analysis rather than the 
classification accuracy we used only default parameters and moreover it ensures the 
reproducibility of results. 
Weka provides implementation for various feature selection belongs to different categories such 
as Filter methods based on univariate statistics (CFSSubsetEval, ChiSquaredAttributeEval), 
based on multivariate statistics (ReliefF), meta-evaluators (CostSensitiveAttributeEval, 
CostSensitiveSubsetEval, FilteredAttribute and SubsetEval), Embedded methods 
(SVMAttributeEval) and other filter methods ConsistencySubsetEval, GainRatioAttributeEval, 
OneRAttributeEval and SymmetricalUncertAttributeEval. We used all the implementations in 
Weka version 3.6 except principal component analysis and latent semantic analysis which 
transforms the set of attributes. Hence, these methods are not widely used for constructing 
classification model. Elastic Net and Lasso (Least Absolute Shrinkage and Selection Operator) 
are two well-known embedded methods that use penalty functions to select the best features.   
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Both these methods have been used for various bioinformatics studies [35]. Glmnet package, 
MATLAB implementation of Elastic Net and Lasso was used for feature selection [37]. 
ReliefF 
ReliefF is one of the widely used instance based attribute ranking scheme [38]. The main idea of 
ReliefF is to iteratively estimate feature weights according to their ability to discriminate 
between neighboring patterns. Each time, random samples are drawn from the dataset and for 
this instance the neighbors of the same class and the opposite class are determined. Based on 
these neighboring cases the weights of the attributes are adjusted [39, 40]. ReliefF doesn’t 
remove statistically dependent attributes but relies on a multivariate relevance criterion that ranks 
the attributes in context of other attributes. 
SVM Attribute Evaluator 
SVM Attribute Evaluator uses recursive feature elimination (RFE) method in combination with 
linear support vector machine (SVM). The algorithm builds a model using linear support vector 
machines and ranks the attributes based on the size of the coefficients. During iteration, it 
computes the attribute ranking criterion for each attribute and removes the attribute with the 
smallest ranking criterion. Finally we will have ranked attributes as output. 
Logistic Model Tree (LMT) 
A Logistic Model Tree (LMT) is an algorithm for supervised learning tasks which combines both 
linear logistic regression and tree induction. Linear logistic regression tries to fit a simple stable 
model to the data with low variance and high bias while the tree induction searches a less 
restricted space of models and capture nonlinear patterns in the data with high variance and low 
bias. LMT combines the best features from both the methods. It creates a model tree with a 
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It combines both the sensitivity and specificity in to one measure and the values lie in the range 
of -1 to +1, while 1 means complete prediction accuracy and 0 means every prediction was 
random [43]. 
3.3 Results 
 3.3.1 Accuracy based on selected analytes 
Accuracy for evaluating a feature selection approach is defined as the overall classification 
performance here, including not only percent agreement with clinical diagnosis (accuracy rate), 
but also area under ROC curve (AUC) and Mathew’s correlation coefficient (MCC), by using 
only the features selected or top-ranked by that feature selection approach. Although this 
definition has been widely used, there’re three key points need to be considered in classification 
processes. First, which classifier is used? Second, how many features are using? Third, highest 
accuracy rate with poor AUC or MCC will NOT be considered as the best accuracy. 
We used training set from partition coverage 1 to select the best features from various methods 
listed above. For fair comparison we choose only the top 12 features which is the least number of 
features selected by most of the methods on partition coverage 1. We know that it is impossible 
to find a classification algorithm that performs well with all feature selection algorithm as every 
classification algorithm has its own learning bias. So in order to find the best combination of 
feature selection and classification algorithm for this kind of proteomics data we choose 20 
different classifiers available in Weka. 
Logistic Model Tree (LMT) performs consistently well for the features selected by different 
set of feature selection algorithm with highest accuracy of 84% and AUC 0,94 for the features 
selected using ReliefF. LMT has been proven to be performing well with the proteomics data 
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with small set of features earlier [25]. So we decided to use LMT as a classifier for further 
analysis. 
Table 3: Results of best classifiers with Top 12 analytes selected using ReliefF and SVM 
Classifier ReliefF SVMAttributeEval 
Accuracy MCC AUC Accuracy MCC AUC 
BaysianLogistic Reg 0.80 0.55 0.77 0.84 0.67 0.85 
Naive Bayesian 0.84 0.63 0.90 0.85 0.66 0.90 
LibSVM 0.83 0.60 0.78 0.85 0.66 0.82 
Logistic 0.80 0.55 0.85 0.81 0.62 0.92 
SMO 0.80 0.54 0.75 0.86 0.71 0.87 
ClassViaRegress 0.83 0.60 0.90 0.78 0.47 0.90 
JRIP 0.80 0.54 0.75 0.77 0.46 0.73 
LMT 0.84 0.63 0.94 0.85 0.67 0.93 
 
Once the classifier was fixed, we tried to identify the best feature selection method by repeating 
the above analysis with all the partitions. The number of attributes selected for classification 
varies between the partitions, depending on the minimum number of features selected by the 
feature selection algorithm for that particular partition. And the results showed that ReliefF and 
SVMAttributeEval classify with better accuracy and AUC for different partitions followed by 
Elastic Net and CostSensitiveAttributeEval. ReliefF achieves highest accuracy of 80% with AUC 
0.90 for partition coverage 1 and SVM achieves 80% accuracy with AUC 0.86 for partition 4.  
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Table 4 Results of top six feature selection methods for partition coverage 4 
Feature Selection method Accuracy MCC AUC 
ReliefFAttributeEval 0.80 0.54 0.90 
SVMAttributeEval 0.75 0.44 0.81 
CostSensitiveAttributeEval 0.70 0.29 0.73 
Elastic Net 0.73 0.36 0.80 
Lasso 0.73 0.36 0.80 
OneRAttributeEval 0.68 0.26 0.69 
 
3.3.2 Efficiency of selected analytes 
Efficiency for evaluating a feature selection approach is defined as the least number of selected 
or top-ranked features used for classification that can achieve the best accuracy.  
Apart from the methods that give the minimum number of features for each partition, there are 
five methods viz... CostSensitiveAttributeEval, ReliefF, SVMAttributeEval, ElasticNet and 
Lasso provide either weights or ranks for all the 146 features. There is a possibility that 
information contained in the top features produced by this algorithm may be lost when we 
compare all the feature selection with the minimum number of features in each partition. So we 
compared the 10 fold classification accuracy and AUC of the top 80 features selected by the five 
methods in the master data set and the results are shown below. 
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Figure 4: Comparison of Accuracy of five feature selection methods 
 
Figure 5: Comparison of AUC of five feature selection methods 
 
As we infer from the figure, all the five methods achieves the highest possible accuracy with 
features not more than 32. Top 32 features selected using SVMAttributeEval classifies the 
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samples with accuracy of 92.5% and AUC 0.98. Both ReliefF and Lasso shows accuracy of 
about 89% and AUC 0.94. OneR is the least performing method in case of both accuracy and 
AUC. As we used 10 fold cross validation accuracy to compare the results, it is no surprise that 
SVMAttributeEval perform better in this case. Since it is an embedded feature selection method 
which uses linear SVM classifier weights to rank the attribute, it may over fit the model.  To 
overcome this problem, we run our analysis in partition coverage using separate training and 
testing set. We compared the predictive power of top features from both ReliefF and 
SVMAttributeEval by reducing the number of features in the multiples of 3. Results shows that 
top 15 features performs better in most of the partitions with ReliefF achieving a maximum 
accuracy of 89% with AUC 0.93 in the case of partition coverage1. 
Table 5: Classification accuracy of Top 30 analytes using LMT 
Classifier ReliefF SVMAttributeEval 
Accuracy MCC AUC Accuracy MCC AUC 
Top 30 features 0.80 0.59 0.89 0.77 0.49 0.83 
Top 27 features 0.84 0.65 0.92 0.80 0.56 0.86 
Top 24 features 0.80 0.56 0.88 0.74 0.41 0.80 
Top 21 features 0.86 0.70 0.92 0.75 0.46 0.81 
Top 18 features 0.86 0.70 0.94 0.74 0.43 0.83 
Top 15 features 0.89 0.75 0.93 0.80 0.57 0.87 
Top 12 features 0.83 0.61 0.90 0.72 0.37 0.81 
Top 09 features 0.80 0.54 0.90 0.75 0.44 0.81 
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3.3.3 Consistency of selected analytes 
We earlier assessed the consistency of the five feature selection algorithm by their prediction 
accuracy with LMT classifier in all the partition. In the five methods, SVMAttributeEval ranks 
the features while all the other four methods assign weight to them. We decided to compare the 
consistency of these methods in selecting analytes across the partition. Since the weight values 
produced by the algorithms are heterogeneous with weights ranging from -1 to 1, 0-100, a 
unified weighting schema was devised.  
First we ranked the features based on their weight values for all the feature selection method 
except SVMAttributeEval for which we already have the ranks available from Weka for all the 
partition. When more than one analyte has same weight, they were alphabetically sorted.  
Once we have the standardized weight for each analyte, the average standard deviation is 
calculated which we call as consistency score. Lower the score, higher the consistency. 
Consistency score for the five methods were shown in table 6. As we infer from the table 6, 
ReliefF has low score of 0.13 with higher consistency in selecting the features across 20 
partitions. It was followed by Lasso and ElasticNet with scores 0.15 and 0.15 respectively. 
   3.3.4 Significance of selected analytes 
We identified that top 32 features selected by the five feature selection methods contributes more 
for the classification. To explore the association between these features and Alzheimer’s disease 
we performed a literature analysis for all the top 32 analytes. We searched the pubmed with 
search criteria ("Analyte" OR "Full Name" OR "Gene Symbol") AND "Alzheimer" and get the 
number of records. A significant score was calculated for each method by taking average of log 
transformed count. Higher the score, more significant are the features selected by the approach. 
The significance here means the agreement between the analytes selected by the feature selection 
 methods 
shows hi
 
Consisten
Significan
Few Supp
Nature 20
PloS one 
ANYAS 2
 
3.3.5 Prot
with the ev
gher signific
Tab
cy score 
ce score 
orted 
07 (18) 
2008 (5) 
008 (89) 
ein Interact
Figur
idence fou
ancy with s
le 6: Consis
ReliefF 
0.13 
1.21 
4 
0 
0 
13 
ion network 
e 6: Integrat
nd in the c
ignificant sc
tency and si
SVM 
0.18 
0.94 
8 
1 
1 
15 
ed CRC net
27 
urrent litera
ore of 1.22 
gnificance sc
OneR E
0.21 
1.07 
8 
0 
0 
10 
work showin
tures. Featu
followed by
ores of Top 
lastic Net 
0.15 
1.22 
6 
3 
3 
16 
g Subnetwo
res selected
 ReliefF and
32 analytes 
Lasso 
0.15 
1.13 
6 
2 
2 
15 
rk signature
 by Elastic
 Lasso.   
Integrated 
N/A 
1.19 
10 
3 
3 
28 
s 
 Net 
 
  28 
We identified that top 32 features selected by the five feature selection methods contributes more 
for the classification. We expanded the top features in HAPPI with confidence score (CI >=0.75, 
i.e. 4-star rating) for interactions, to obtain a protein-protein interaction (PPI) network. 
3.4 Discussion 
Sub network 1 shows the GPCR Signaling pathway induced by Follicle Stimulating Hormone 
(FSH), Luteinizing Hormone (LH) and pancreatic polypeptide (PPY). Both FSH and LH has 
been linked to Neuroactive ligand receptor interaction pathway too. G Protein Coupled 
Receptors (GPCRs) are involved in the process of cleavage of amyloid precursor proteins and 
also in various key neurotransmitters system. There are various studies which supports the notion 
that GPCRs and activation of their downstream signal cascades increases the non-amyloidogenic 
processing of APP [44, 45]. GPCRs are also involved in neuroinflammation and plays role in 
Amyloid β mediated toxicity. Class A receptors of GPCRs seen in the hippocampus and cortex 
of the brain are abundantly expressed in the microglial cells of AD patients. Several attempts had 
been made to use this adenosinergic system as a potential therapeutic target for managing 
cognitive dysfunction in AD [46]. Though the involvement of these hormones with AD has been 
reported earlier, role of hormone induced GPCR signaling in AD is quite a fascinating one. 
Surprisingly both FSH and LH induce GPCR signaling through Class A receptors. This provides 
an interesting insight in to the pathways involved in AD which could be a potential therapeutic 
target and complement the current treatment approaches that focus mainly on secretase inhibitors 
and amyloid immunotherapy.  
Analytes from sub network 2 involved in four pathways viz. lipid metabolism, Complement 
activation, Renin Angiotensin System and Hemostasis. Role of Lipid metabolism in AD has been 
well known with central obesity is related to a high risk of Late Onset Alzheimer’s disease 
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(LOAD) [47]. Apart from this, the majority of the analytes from this sub network involves in 
complement and coagulation pathways. The interactions between the components in complement 
activation pathways and hemostasis is well established [48]. Both the complementation cascade 
and the blood clotting were activated by same kind of stimuli. Multiple regulatory loops between 
these two systems provide an effective host response against infection. Complement system 
activation due to accumulation of Amyloid β and the involvement of other key analytes in 
hemostasis was captured in sub network 2.  
Sub network 3 connected to network 2 through C3 has around 8 analytes that involves in 
Cytokine – cytokine receptor interaction and Chemokine signaling. Cytokines plays crucial role 
in innate and adaptive inflammatory responses, cell growth, differentiation, angiogenesis and 
homeostasis. There are considerable evidences to suggest that an inflammatory response is 
involved in the AD neurodegenerative cascade. A detailed review on the cytokine AD 
association highlighted the elevated levels of several key analytes that was shown in sub network 
2 such as TNF-α, IL-6r, IL-16 and IL-1847. 
Sub network 4 shows analytes that involves in various pathways such as Cytokine – cytokine 
receptor interaction, various cancer pathways (Pancreas and Bladder cancer), Hemostasis and 
mTOR Signalling pathway. Analytes that participates in cancer related pathways are involved in 
two key processes, while Epidermal Growth Factor (EGF) involves in evading apoptosis, 
Vascular Endothelial growth factor (VEGF) and Matrix metallopeptidase 1 (MMP1) involves in 
VEGF Signaling which eventually helps in Angiogenesis. Moreover, mTOR signaling pathway 
plays a central role in various neuronal functions and maintains hemostasis, it also regulates 
different forms of learning and memory. 
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Another promising feature in the integrated network is the coherence between the sub networks 
achieved through bridge analytes. Sub network 1 connects to sub network 4 through Insulin-like 
growth factor binding protein 2 (IGFB2). Insulin signaling plays a role in learning and memory 
and deregulated insulin signaling occurred in the brains of patients with AD[46]. Hence Type 2 
diabetes has been identified as a major risk factor for AD, and the onset of diabetes worsens 
cognitive disorders even in the absence of amyloid plaques. Cognitive decline associated with 
neuronal cell death (apoptosis) has been targeted in AD treatment using anti diabetic medicine. 
IGFB2 involves in insulin signaling pathway which controls vital brain functions such as cell 
survival, energy metabolism and neuroregeneration [49]. Similarly, sub network 2 connects with 
GPCR Signaling sub network 4 through AAT and with Sub network 2 through analytes that in 
complement system activation.  
We also confirmed the results from sub network by Gene Ontology (GO) analysis. Results from 
GO performed with DAVID and pathway analysis with Kyoto Encyclopedia of Genes and 
Genomes (http://www.genome.jp/kegg/) and Reactome 
(http://www.reactome.org/ReactomeGWT/entrypoint.html) also confirmed the involvement of 
the selected analytes in Chemokine Signalling pathway, Hematopoetic Cell Lineage, 
Complement Activation pathway and Focal Adhesion. 
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4. INTEGRATIVE NETWORK ANALYSIS OF MICRO RNA AND MRNA 
4.1 Background 
4.1.1 MDSC and T-cell suppression 
Myeloid derived suppressor cells (MDSC) constitute a unique component of immune system that 
expand during cancer, inflammation, and infection, and capable of suppressing T-cell responses. 
In addition to T-cell suppression, MDSCs have also been linked to innate immune response 
regulation through cytokines. MDSCs were described more than 20 years ago in patients with 
cancer and found to play significant roles in tumor angiogenesis and metastasis [50]. They are 
heterogeneous group of cells that consists of myeloid progenitor cells and immature myeloid 
cells (IMCs). In normal conditions, these IMCs matures in to granulocytes, macrophages and 
dendritic cells, while in pathological conditions such as cancer, auto immune disorders, sepsis 
and in some infectious disease, a partial block in the differentiation of IMCs in to mature 
myeloid cells results in the expansion of this population. It results in upregulation of immune 
suppressive Arginase 1 (ARG1), inducible Nitric oxide synthase (iNOS), Nitric oxide (NO) and 
Reactive oxygen Species. 
In Mouse, MDSCs are characterized by the co-expression of myeloid cell differentiation antigen 
(GR-1) and CD11b (α integrin). Subtypes of MDSC have been defined in the mouse based on the 
antibody specificity of GR1’s two epitopes LY6G and LY6C. Granulocytic MDSCs have a 
CD11b+Gr1+ phenotype, whereas MDSCs with monocytic morphology are CD11b+Gr1-. These 
two subsets have different functions in cancer, infectious and auto immune diseases and employs 
different mechanism to suppress T cell function. Mouse bone marrow has 20-30% of these cells, 
while spleen has 2-3% and absent completely in Lymph nodes. Previous studies had observed 
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significant functional activity in freshly isolated cells at the site of infection (functional MDSC) 
while it is completely absent in peripheral cells (MDSC precursors) [51].  
4.1.2 MicroRNA and Immune system 
Micro RNAs are small, single stranded non-coding RNAs that are involved in the regulation of 
protein expression in many biological systems. They are about 22 nucleotides long and they 
predominantly bind to the 3’ untranslated region (3’UTR) of messenger RNAs (mRNAs) to 
inhibit translation or to induce cleavage. So far more than 700 miRNAs have been identified in 
human genome and each have the potential to suppress the expression of thousands of genes. 
More than 100 different miRNAs are expressed by cells of the immune system; they have the 
potential to broadly influence the molecular pathways that control the development and function 
of innate and adaptive immune responses. Depending on the nature of the target, miRNAs have 
tumor suppressive or tumor promoting effect on various cancers of immunological origin [52]. 
In this study, we identified and validated crucial miRNA-gene associations that can be used to 
study the difference in the molecular mechanism between functional MDSCs and MDSC 
precursor. We have compiled all the existing Micro RNA resources and used a knowledge 
guided approach to build an integrated miRNA-gene network to identify the significant genes. 
miRNAs and pathways through which functional MDSCs differ from their precursors. 
4.2 Approach 
4.2.1 Differential expression analysis 
We isolated both the granulocytic (Ghigh) and monocytic (G low) subtypes of MDSC cells from 
spleen and peritoneal cavity (PC) that has a peritoneal tumor. Spleen cells are Ghigh or G low.  
Peritoneal cavity cells are Glow, Gmid and Ghigh. Totally, there are six contrast groups: PC Ghigh vs. 
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Sp Ghigh, PC Gmid vs. Sp Ghigh, PC Glow vs. Sp Ghigh, PC Ghigh vs. Sp Glow, PC Gmid vs. Sp Glow, PC 
Glow vs. Sp Glow. We have mRNA arrays (GeneChip® Mouse GENE 1.0 ST) and micro-RNA 
arrays (GeneChip® miRNA array) from the same RNA samples. 
 Data preprocessing, including quality control and normalization, will be implemented by using 
standard packages in Bioconductor. Filters based on fold changes, p-values, and detection 
numbers will be applied to obtain differential miRNAs for each contrast group. Criteria of 
miRNA array filters will be determined based on existing literatures [53]. 
For the same six contrast groups, data preprocessing, including quality control and 
normalization, will also be implemented by using standard packages in Bioconductor. Filters 
based on fold changes, p-values, and presence/absence calls of mRNA probe IDs will be applied 
to obtain differential genes for each contrast group. In many cases, crucial genes show relatively 
slight changes, and many genes selected are also poorly annotated [2]. So criteria of mRNA 
array filters will be determined according to how many genes are finally obtained.  
4.2.2 Data integration for miRNA-gene associations 
Table 7 shows some of the primary databases that provide a comprehensive view of microRNAs.  
Table 7: Primary microRNA databases and feature comparisons 
Database 
 
Features 
miRBase HMDD miRecords TarBase miR2Disease miRGator miRo 
Target Gene 
Information 
 
Only 
Predicted 
genes 
NA 
Predicted 
and 
Validated 
genes 
Only 
Validated 
genes 
Yes Yes Yes 
Disease NA Yes NA NA Yes Yes NA 
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Association 
Gene 
Ontology 
NA NA NA NA NA NA Yes 
Download Yes Yes Yes Yes Yes Yes Yes 
Statistics for 
Human 
1048 
records 
450 miRNA 
genes, 258 
diseases,  
548 
miRNAs, 
1579 target 
genes 
1300 
validated 
targets 
349 miRNA, 
134 Disease 
Expression 
profile  
NA 
Comments 
Central 
Repository 
of miRNA  
Tissue & 
Gene wise 
disease 
association 
Largest 
source of 
validated 
target 
Second 
largest of  
validated 
targets 
HMDD with 
Additional 
features 
Expression 
Profile 
GO info 
 
There are around 12 prediction tools (Table 8 shows main 8 tools of them) are available which 
can predict the miRNA-targeted genes. These algorithms uses various structural features such as 
hairpin length, hairpin loop length, thermodynamic stability of miRNA-mRNA duplex, base 
pairing, and distance of microRNA from the loop of its hairpin precursor; and sequence features 
such as nucleotide content and location, 3`UTR sequence complementarity, and nucleotide 
repeats [54]. However, for the most part, all these target prediction methods generate a large 
number of false positives. Several algorithms addressed this problem by considering 
conservation of sequences across the species which eliminates poorly conserved sites [55]. 
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Table 8: Tools for microRNA-targeted gene prediction and feature comparisons 
Database 
 
 
Features 
miRDB TargetScan picTar 
	
microRNA 
 
RNAhybrid 
Diana 
MicroT 
PITA 
Search 
Features 
miRNA, 
Gene 
Name and 
batch  
Gene Name 
miRNA 
and Gene 
Name 
miRNA 
name 
miRNA 
sequence(s) 
miRNA, 
Gene Name 
miRNA 
sequence 
Download Yes Yes No Yes Yes Yes Yes 
Statistics 
2295 
microRNA 
17821 
Human 
Genes 
NA 
1100 
Human 
miRNA  
 
NA NA 
NA 
 
Update 
April 2009 
Release 5.2, 
June 2011 
March 26, 
2007 
August 
2010 
2006 April 2009 NA 
Comments 
SVM 
based 
target 
prediction 
method. 
Sequence 
similarity 
and 
conservation 
Mouse 
based, 
looks for 
conservati
on in 
Human 
Official 
source of 
expression 
profile 
Free energy  
Has 
miRPath and 
miRExtra 
tools 
Seq. 
similiarit
y 
A recent review paper [56] shows that three computational algorithms - TargetScan, 
DianaMicroT and miRanda/mirSVR can provide miRNA target gene prediction with higher 
precision. TargetScan 5.2 [57]  is one of the most widely used microRNA prediction algorithm. 
It predicts the microRNA binding sites through the identification of 7 nucleotide seed matches on 
the 3`UTR of mRNAs and the assessment of their evolutionary conservation across several 
species. It uses RNA Fold to calculate thermodynamic free energy of the binding, and scores 
both the single and multiple binding sites. DianaMicroT [58] is an algorithm based on several 
parameters calculated individually for each microRNA and it combines conserved and non-
conserved microRNA recognition elements (MRE) in to a final prediction score. The total 
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predicted score of a miRNA-gene association is the weighted sum of conserved and unconserved 
MREs of a gene. Both DianaMicroT and TargetScan estimated to achieve a precision level of 
66% and 60% respectively in a recent study, outperforming most other prediction algorithms. 
Algorithm miRanda [59] uses a position weighted matrix to emphasize binding on microRNA 
5`end segment, uses RNA Fold for free energy calculation and relies on evolutionary 
conservation of binding sites. Algorithm mirSVR [55] is a most recent machine learning method 
that ranks microRNA target sites by a down regulation score. The algorithm trains a regression 
model using the sequence and contextual features extracted from the target sites predicted by 
miRanda, thereby combining the efficiency of two methods. Algorithm miRanda/mirSVR is 
competitive with other target prediction methods and in addition it has a unique ability to predict 
the extent of downregulation by specific miRNA at mRNA or protein level. Importantly, this 
method identifies a significant number of experimentally determined non-canonical and non-
conserved sites. All these three algorithms will be used to predict the genes targeted by specific 
miRNAs in our project. 
4.2.3 Correlation analysis between miRNA and mRNA arrays 
Both Pearson’s correlation and Spearman’s correlation (non-parametric) will be calculated to 
correlate the expressions of all miRNAs with all mRNAs through all samples. According to the 
distributions of miRNA arrays and mRNA arrays, filters based on correlation coefficients and p-
values will be applied to obtain statistically significant miRNA-gene correlations. Then the 
filters based on fold changes, p-values, and detection numbers of miRNAs will also be applied to 
obtain statistically significant miRNA-gene correlations for differential miRNAs. These 
differential miRNA-gene correlations will be used as a supplementary data for miRNA-gene 
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associations retrieved from databases and computational prediction after a functional enrichment 
validation. 
4.2.4 Validation for miRNA-gene associations at pathway-level 
Since miRNA-gene association data retrieved from databases is far from complete, while 
miRNA-gene association data predicted by computational algorithms is very noisy (high FPR - 
false positive rate), it is not easy to validate miRNA-gene correlations from miRNA and mRNA 
array correlation analysis at molecule-level. Hence, functional enrichment for miRNA target 
genes will be processed for miRNA-gene association validation first. For functional enrichment, 
both pathway analysis and Gene Ontology (GO) analysis will be applied. 
As shown in Table 9, there are six online tools which can be used for miRNA target gene 
functional enrichment and pathway analysis. Of these tools, Diana miRPath uses only list of 
miRNAs to predict target genes and enrich these predicted genes in KEGG pathways, while 
other tools requires array datasets. We will mainly use miRPath for microRNA-targeted gene 
functional enrichment analysis at pathway-level. 
Table 9: Tools for miRNA target gene functional enrichment and annotation 
Database 
 
Features 
miRPath miTALOS Magia miRGen mirAct 
Target Gene 
Information 
Uses DianaMicroT 
to predict gene 
Uses 
TargetScan 
miRanda, 
PITA & 
TargetScan 
From miRanda, 
picTar, 
TargetScan & 
DianaMicroT 
miRanda, 
picTar, 
TargetScan & 
PITA 
Functional KEGG KEGG, tissue GO, Network Maps to UCSC Clustering 
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Annotation specific 
expression 
enrichment genome 
browser 
Expression 
Profiling 
No Yes 
Based on user 
input 
No 
User Input 
data 
Comments 
Both single and 
batch processing 
Tissue specific 
enrichment 
method 
Analyze user 
input exp. 
Data 
Positional 
relationships & 
Cluster info 
Using 
expression 
data 
First, miRNAs will be input into miRPath (and other tools will be also tested) for target gene 
prediction and functional enrichment, which will generate a list of pathways ranked by -log(p-
value) [60]. Second, experimentally-validated miRNA target genes will be enriched in a 
comprehensive human pathway database (HPD) [61], which has integrated heterogeneous 
pathways from five data sources - NCI-Nature curated Pathway Interaction Database (PID), 
Reactome, BioCarta, KEGG and ProteinLounge. An online pathway analysis tool based on HPD 
will also generate a list of pathways ranked by similarity scores [62]. Third, two ranked pathway 
lists will be compared to assess whether predicted miRNA target genes have same enriched 
functions with experimentally-validated miRNA target genes at pathway-level. Finally, 
differential miRNA-gene correlations will also be validated by the same way of pathway 
enrichment analysis, but using both experimentally-validated and computationally-predicted 
miRNA target genes. 
4.2.5 Network of differential miRNAs and genes  
An integrated network will be constructed to connect miRNAs and genes differentially-
expressed in miRNA arrays and mRNA arrays respectively. First, differential miRNAs will be 
connected to target genes from the above integrated miRNA database and also computational 
predictions. Validated miRNA-gene correlations will be also added into connections. Second, 
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differential genes will be connected to the genes targeted by differential miRNAs by using high-
quality interactions from the human annotated and predicted protein interaction  (HAPPI) 
database [63]. One or two intermediate proteins will be used to bridge the connections. Third, we 
will integrate miRNA-gene associations and gene/protein-gene/protein interactions together, to 
build the network connecting differential miRNAs and differential genes. Finally, the 
comprehensive network will not only provide a systems-level view for the study on functional 
activities of MDSCs, but will also serve as a molecular interaction network model to identify 
significant miRNAs and genes, which could be used as biomarkers to distinguish functional 
MDSCs from MDSC precursors. 
4.3 Results 
Of the six contrast groups in this preliminary study on mRNA arrays for MDSC, we focused on a 
result of 2-way ANOVA analysis on PC Glow vs. SP Glow contrast in mRNA arrays. From a 
recent review [50], we selected 11 MDSC-related genes - ARG1, NOS2, IL1RL2, VDR, 
SLC7A2, TLR4, FOLR2, HIF1A, S100A9, CEBPB, and S100A8, which are all differentially 
expressed in PC Glow vs. SP Glow contrast from mRNA arrays (each group has 4 samples). 
4.3.1 Experimentally validated miRNA-gene association network 
We focused on a result of 2-way ANOVA analysis on PC Glow vs. SP Glow contrast in miRNA 
arrays (each group has 4 samples). From differential analysis, 153 miRNAs, of which 13 are 
duplicates (Same miRNA from different species), have been selected by using the filter (p-value 
<=0.05 and |Fold Change| >= 1.5). We combined 153 experimentally-validated miRNA-gene 
associations from two databases (miRecords and Tarbase) and 42 protein-protein interactions 
with 4-5 star quality retrieved from HAPPI to build a differential miRNA targeted gene network, 
shown in Figure 5. The network contains 35 differential miRNAs having target genes (validated 
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4.3.3 Validation of computationally predicted association 
Based on the three computational miRNA-gene association prediction algorithms - TargetScan, 
DianaMicroT and miRanda/mirSVR, 153 miRNAs (after removing duplicates, 115 unique 
miRNAs) have potentials to target these 11 significant MDSC-related genes. By using the filter 
(p-value <=0.05, |Fold Change| >= 1.5, and Max detection number > 0), 5 differential miRNAs 
(4 of which are in the network shown in Figure 1) are selected: 
 mmu-miR-106a → HIF1A, NOS2 
 mmu-miR-125a → VDR, SLC7A2 
 mmu-miR-19b → HIF1A 
 mmu-miR-204 → S100A9 
 mmu-miR-351 → SLC7A2, VDR 
By using miRPath, top-10 KEGG pathways associated with these 5 miRNAs are listed below:  
(a) Axon guidance (b) MAPK signaling pathway  (c) Long-term potentiation (d) Insulin 
signaling pathway (e) mTOR signaling pathway (f) Renal cell carcinoma (g) Melanogenesis 
(h) Glioma (i) Chronic myeloid leukemia (j) Focal adhesion 
Most of the pathways (highlighted with fold font) are overlapped with the pathways enriched in 
HPD from the 5 differential miRNA-targeted genes, which implies that computationally-
predicted miRNA-gene associations can be trusted at pathway-level. 
We used an online gene set analysis toolkit Web Gestalt [64] for Gene Ontology (GO) analysis. 
Significant genes overrepresentation was found by hypergeometric statistical. Genes were 
enriched in the following three sub categories which are strongly associated with signal 
transduction pathways in immune response.   
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data. Currently, gene expression signature analysis and pathway analysis remains two separate 
processes, since in many cases, extensive data preprocessing, comprehensive gene selection 
statistics, and downstream pathway/network analysis cannot be replaced by GSEA. Having a 
single repository for comprehensive disease associated gene and network/pathway enrichment 
analysis will be of great use to the scientific community. As a future study, we decided to build 
an integrated online database - Pathway and Gene Enrichment Database (PAGED), to enable 
comprehensive search for phenotype-associated gene sets, network modules, and pathways, by 
integrating gene set based molecular patterns at three dimensions – DNA/genome, 
RNA/transcriptome, and Protein/proteome. First, disease-gene association data are curated and 
integrated from Online Mendelian Inheritance in Man (OMIM) database and Genetic 
Association Database (GAD). Second, functionally-grouped gene sets are evaluated and 
integrated by using gene signatures in Molecular Signatures Database (MSigDB) and Gene 
Signatures Database (GeneSigDB). Third, signaling pathways/protein interaction networks and 
transcription factors/gene regulatory networks are retrieved from Human Pathway Database 
(HPD) and Human Annotated and Predicted Protein Interaction (HAPPI) database. This 
integrated database will be of great use to the system biology studies on high throughput data 
sets. 
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